| Inventor | Institute |
|---|---|
| Irene Leigh | Queen Mary University of London |
| SKU: | 151123 |
|---|---|
| Product description: | Monoclonal antibody used to detect keratin 16 mutations within epithelial tissues. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | A synthetic peptide corresponding to an amino acid sequence of the carboxyl terminus of human keratin 16. |
| Immunogen Uniprot ID: | P08779 |
| Myeloma used: | Sp2/0-Ag14 |
| Cat. #: | 151123 |
|---|---|
| Provenance and Ownership: | The Anti-Keratin16 [LL025] is owned by Cancer Research UK. CancerTools supplies the Anti-Keratin16 [LL025] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-Keratin16 [LL025] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell signaling and signal transduction |
| Application: | IHC ; IF ; IP ; WB |
| Target: | Keratin 16 |
| Reactivity: | Human |
| Clone: | LL025 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | Keratins are a family of intermediate filament proteins that assemble into filaments through forming heterodimers of one type I keratin (keratins 9 to 23) and one type II keratin (keratins 1 to 8). Keratins demonstrate tissue and differentiation specific expression profiles. Keratin 16 is expressed in suprabasal keratinocytes of wounded epidermis. Keratin 16 suprabasal expression is found in situations of high cell turnover. Mutations in the gene encoding keratin16 are associated with the genetic skin disorders including pachyonychia congenita, non-epidermolytic palmoplantar keratoderma and unilateral palmoplantar verrucous nevus. LL025 reactivity was completely negative in normal breast tissue and non-invasive breast carcinoma. However, 10% of the invasive carcinomas tested were diffusely or focally positive with this antibody. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | Store at -20° C frozen. Avoid repeated freeze / thaw cycles |
| Shipping conditions: | Dry ice |
| References: |
Hughes BR et al. 1996. Br. J. Dermatol. 134(2):247-56.PMID: 8746337 Wong et al. 2019. Sci Rep. 9(1):18561. PMID: 31811191. Frew et al. 2018. F1000Res. 7:1923. PMID: 31281635. Boink et al. 2018. J Tissue Eng Regen Med. 12(2):e1088-e1097. PMID: 28388010. Ojeh et al. 2017. PLoS One. 12(3):e0174389. PMID: 28350869. Porter et al. 2000. Lab Invest. 80(11):1701-10. PMID: 11092530. K15 expression implies lateral differentiation within stratified epithelial basal cells. de Berker et al. 1995. Exp Dermatol. 4(6):350-6. PMID: 8608342. Keratin expression in discoid lupus erythematosus. Markey et al. 1992. Br J Dermatol. 126(2):154-60. PMID: 1371396. Keratin expression in basal cell carcinomas. Wetzels et al. 1991. Am J Pathol. 138(3):751-63. PMID: 1705754. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.